Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on AngioDynamics but lowers the price target from $13 to $12.
October 04, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on AngioDynamics but reduces the price target from $13 to $12, indicating a slightly less optimistic outlook.
The maintained Buy rating suggests continued confidence in AngioDynamics' potential, but the lowered price target reflects a slightly reduced growth expectation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100